-
1161
Construction and characterization of bioluminescent Salmonella Reading outbreak and non-outbreak strains
Published 2025-02-01Get full text
Article -
1162
-
1163
Salivary Protein Profile and Food Intake: A Dietary Pattern Analysis
Published 2021-01-01Get full text
Article -
1164
-
1165
-
1166
Macrophage P2X7 Receptor Function Is Reduced during Schistosomiasis: Putative Role of TGF-β1
Published 2014-01-01Get full text
Article -
1167
-
1168
-
1169
Nanoemulsified Butenafine for Enhanced Performance against Experimental Cutaneous Leishmaniasis
Published 2021-01-01Get full text
Article -
1170
The Influence of Monoamine Oxidase Variants on the Risk of Betel Quid-Associated Oral and Pharyngeal Cancer
Published 2014-01-01Get full text
Article -
1171
Kojic Acid Derivative as an Antimitotic Agent That Selectively Kills Tumour Cells
Published 2024-12-01Get full text
Article -
1172
-
1173
Effectiveness of PK-Guided Personalized Recombinant FVIII Treatment in Patients with Hemophilia A: Clinical Case Experiences Based on an Observational Study
Published 2025-01-01“…Yoko Mizoguchi,1 Moeko Hino,2 Hitoshi Ueda,3 Yasuo Miyaguchi,3 Masao Kobayashi1,4 1Department of Pediatrics, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, Japan; 2Department of Pediatrics, Chiba University Hospital, Chiba, Japan; 3Japan Medical Office, Takeda Pharmaceutical Company Limited, Tokyo, Japan; 4Japanese Red Cross, Chugoku-Shikoku Block Blood Center, Hiroshima, JapanCorrespondence: Yasuo Miyaguchi, Japan Medical Office, Takeda Pharmaceutical Company Limited, 2 Chome-1-1 Nihonbashihoncho, Chuo-ku, Tokyo, 103-0023, Japan, Tel +81 70-4921-7966, Email yasuo.miyaguchi1@takeda.comPurpose: Prophylaxis with recombinant factor VIII (rFVIII) products is the gold-standard treatment for hemophilia A. …”
Get full text
Article -
1174
-
1175
-
1176
Family caregiver frailty in adult congenital heart disease is overlooked: A call to action
Published 2025-03-01Get full text
Article -
1177
-
1178
-
1179
-
1180